Latest news

• AstraZeneca sells Losec rights as part of refocus strategy

  its chronic obstructive pulmonary disease (COPD) therapy PT010 (budesonide/glycopyrronium/formoterol fumarate).

• AZ builds case for its COPD triple as it chases GSK’s Trelegy

  In KRONOS, there was a 52% reduction in the rate of moderate or severe COPD exacerbations with Breztri compared with AZ’s two-drug Bevespi glycopyrronium/formoterol fumarate, and a 17% ... Breztri – which combines long-acting beta agonist (LABA)

• Circassia seeks shift to AIM after failing LSE criteria

  Duaklir (aclidinium/formoterol) which is under regulatory review in the US with a verdict due by the end of March.

• AZ prepares to file COPD triple, taking on rival GSK

  The KRONOS trial of PT010 – which combines long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid (ICS) budesonide – was presented at a medical congress ... It was

• AZ rival to GSK’s COPD drug Anoro fails head-to-head test

  The results of the AERISTO trial are a blow to AZ’s ambitions for Bevespi (glycopyrronium/formoterol fumarate) – a long-acting muscarinic agonist (LAMA)/long-acting beta agonist (LABA) combination that ... while AZ’s PT010